A Phase II Trial of The Oral Mtor Inhibitor Everolimus in Relapsed Hodgkin Lymphoma

PURPOSE: Everolimus is an oral antineoplastic agent that targets the raptor mammalian target of rapamycin (mTORC1). The phosphatidylinositol 3-kinase/mTOR signal transduction pathway has been demonstrated to be activated in tumor samples from patients with Hodgkin Lymphoma (HL). The goal of this tri...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Am J Hematol
Main Authors: Johnston, Patrick B., Inwards, David J., Colgan, Joseph P., LaPlant, Betsy R., Kabat, Brian F., Habermann, Thomas M., Micallef, Ivana N., Porrata, Luis F., Ansell, Stephen M., Reeder, Craig B., Roy, Vivek, Witzig, Thomas E.
Format: Artigo
Sprog:Inglês
Udgivet: 2010
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4420736/
https://ncbi.nlm.nih.gov/pubmed/20229590
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.21664
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker